生技藥品市場規模、佔有率及成長分析（按類型、藥物類別、治療用途、來源、製造業及地區）－2025-2032 年產業預測

2023 年生技藥品市場規模價值為 5,113 億美元，預計將從 2024 年的 5,675.4 億美元成長到 2032 年的 1,3079.2 億美元，預測期內（2025-2032 年）的複合年成長率為 11.0%。

受生物技術進步和標靶治療需求不斷成長的推動，全球生技藥品市場呈現強勁成長。生技藥品，即從生物來源中提取的藥物化合物，徹底改變了癌症、自體免疫疾病和感染疾病等慢性疾病的治療模式。他們的客製化創新方法改善了患者的治療效果，並將生物製藥定位為現代醫療保健的關鍵組成部分。市場成長的主要驅動力是糖尿病和關節炎等慢性疾病的日益流行，這反過來又需要有效的治療方案。然而，由於這些生技藥品會受到溫度和環境條件的影響，因此在整個供應鏈中維持其完整性仍然存在挑戰。美國生技藥品市場預計將持續成長，展現出生物製藥在改善生活品質和控制疾病方面的巨大潛力。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

生技藥品市場規模（按類型）

• 市場概覽
• 腫瘤壞死因子（TNF）抑制劑
• T細胞抑制劑
• 選擇性共刺激調節劑
• 白細胞介素-6 (IL-6) 或白細胞介素-17 阻斷劑
• 白細胞介素-1（IL-1）阻斷劑
• B細胞抑制劑

生技藥品市場規模（依藥物類別）

• 市場概覽
• 單株抗體
• 重組胰島素
• 疫苗
• 血液因素
• 人體生長荷爾蒙
• 促紅血球生成素
• 融合蛋白
• 重組酵素
• 干擾素
• 集落刺激因子
• 基因治療
  • 細胞療法
  • 寡核苷酸
  • 其他
• 胜肽
• 肉毒桿菌毒素
• 其他

生技藥品市場規模（依治療用途分類）

• 市場概覽
• 腫瘤學
• 自體免疫疾病/免疫疾病
• 代謝紊亂
• 眼科疾病
• 呼吸系統疾病
• 發炎性腸道疾病（IBD）
• 神經系統疾病
• 心血管疾病（CVD）
• 肌肉骨骼疾病（MSD）
• 感染疾病
• 其他

生技藥品市場規模（依來源）

• 市場概覽
• 微生物
• 哺乳動物
• 其他

按製造業分類的生技藥品市場規模

• 市場概覽
• 外包
• 內部製造

生技藥品市場規模（依藥物類型分類）

• 市場概覽
• 品牌藥物
• 學名藥

以採購方式生技藥品市場規模

• 市場概覽
• 處方藥
• 場外交易（OTC）

生技藥品市場規模（以劑型分類）

• 市場概覽
• 注射
• 錠劑
• 其他

生技藥品市場規模（依給藥途徑）

• 市場概覽
• 腸外
• 口服
• 其他

生技藥品市場規模（以最終用戶分類）

• 市場概覽
• 醫院
• 專科診所
• 居家護理
• 其他

生技藥品市場規模（按分銷管道）

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

生技藥品市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Roche Holding AG（Switzerland）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Amgen Inc.（USA）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK）
• Biogen Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim（Germany）
• Samsung Biologics（South Korea）
• Lonza Group AG（Switzerland）
• WuXi Biologics（China）
• Celltrion, Inc.（South Korea）
• Grifols, SA（Spain）

結論和建議

Biologics Market size was valued at USD 511.3 billion in 2023 and is poised to grow from USD 567.54 billion in 2024 to USD 1307.92 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The global biologics market has demonstrated robust growth, driven by advancements in biotechnology and the rising demand for targeted therapies. Biologics, pharmaceutical compounds sourced from living organisms, have shifted the landscape of treatment for chronic conditions, including cancer, autoimmune disorders, and infectious diseases. Their tailored and innovative approaches enhance patient outcomes, positioning biopharmaceuticals as critical components in modern healthcare. Key market growth drivers include the escalating prevalence of chronic diseases, such as diabetes and arthritis, necessitating effective treatment options. However, challenges remain in maintaining the integrity of these biologics throughout the supply chain, influenced by temperature and environmental conditions. The US biologics market is set for sustained growth, indicating promising prospects for biopharmaceuticals in improving quality of life and disease management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biologics Market Segments Analysis

Global Biologics Market is segmented by Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker and B-cell Inhibitor. Based on Drug Class, the market is segmented into Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Peptide, Botulinum Toxin and Others. Based on Therapeutic Application, the market is segmented into Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases and Others. Based on Source, the market is segmented into Microbial, Mammalian and Others. Based on Manufacturing, the market is segmented into Outsourced and In-House. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Mode of Purchase, the market is segmented into Prescription Drugs and Over-The-Counter (OTC) Drugs. Based on Dosage Form, the market is segmented into Injection, Tablets and Others. Based on Route of Administration, the market is segmented into Parenteral, Oral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biologics Market

The rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, has significantly spurred the demand for innovative biological therapies. These advanced treatments leverage targeted approaches, distinguishing them from traditional chemical-based medications and enhancing their effectiveness. As a result, the biologics market is experiencing substantial growth, driven by the need for more precise and efficient therapeutic options. This trend reflects a broader shift toward personalized medicine, where tailored treatments not only improve patient outcomes but also foster ongoing advancements in biopharmaceutical research and development, further propelling the market forward.

Restraints in the Biologics Market

The biologics market faces significant challenges due to the intricate and expensive processes involved in the development and production of natural products. The stringent regulatory standards in place can limit both the affordability and accessibility of biologic therapies, ultimately hindering market growth. As companies navigate these challenges, the high costs associated with compliance and manufacturing may deter investment and innovation, which could further stifle advancements in biologic treatments. Consequently, the interplay between regulatory demands and production complexities remains a critical restraint for the biologics market, impacting its overall potential and reach in the healthcare industry.

Market Trends of the Biologics Market

The Biologics market is witnessing a significant shift towards personalized medicine, fundamentally transforming therapeutic approaches. This trend emphasizes the development of biologic therapies tailored to the unique genetic profiles and specific disease characteristics of individual patients, leading to more effective and targeted treatments. As a result, innovation in biological sciences is accelerating, with advancements in areas such as monoclonal antibodies, gene therapies, and regenerative medicine. The growing demand for precision therapies is propelling investments and research in this field, expanding the scope and applications of biologics in managing various diseases, thus positioning the market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Biologics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Tumor Necrosis Factor (TNF) Inhibitor
• T-cell Inhibitor
• Selective Co-stimulation Modulators
• Interleukin-6 (IL-6) or Interleukin-17 Blocker
• Interleukin-1 (IL-1) Blocker
• B-cell Inhibitor

Global Biologics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibody
• Recombinant Insulin
• Vaccine
• Blood Factor
• Human Growth Hormone
• Erythropoietin
• Fusion Protein
• Recombinant Enzyme
• Interferon
• Colony-stimulating Factor
• Gene Therapy
  • Cell Therapy
  • Oligonucleotides
  • Others
• Peptide
• Botulinum Toxin
• Others

Global Biologics Market Size by Therapeutic Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Autoimmune/Immunologic Diseases
• Metabolic Disorders
• Ophthalmic Diseases
• Respiratory Disorders
• Inflammatory Bowel Diseases (IBDs)
• Neurological Disorders
• Cardiovascular Diseases (CVDs)
• Musculoskeletal Disorders (MSDs)
• Infectious Diseases
• Others

Global Biologics Market Size by Source & CAGR (2025-2032)

• Market Overview
• Microbial
• Mammalian
• Others

Global Biologics Market Size by Manufacturing & CAGR (2025-2032)

• Market Overview
• Outsourced
• In-House

Global Biologics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded Drugs
• Generic Drugs

Global Biologics Market Size by Mode of Purchase & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Global Biologics Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Injection
• Tablets
• Others

Global Biologics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Parenteral
• Oral
• Others

Global Biologics Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Biologics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Biologics Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations